GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (OTCPK:GNMSF) » Definitions » Cyclically Adjusted Revenue per Share

Genmab A/S (Genmab A/S) Cyclically Adjusted Revenue per Share : $15.45 (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Genmab A/S Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Genmab A/S's adjusted revenue per share for the three months ended in Dec. 2023 was $10.364. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $15.45 for the trailing ten years ended in Dec. 2023.

During the past 12 months, Genmab A/S's average Cyclically Adjusted Revenue Growth Rate was 29.50% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 35.60% per year. During the past 5 years, the average Cyclically Adjusted Revenue Growth Rate was 38.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Genmab A/S was 42.30% per year. The lowest was 32.80% per year. And the median was 36.70% per year.

As of today (2024-04-30), Genmab A/S's current stock price is $274.22. Genmab A/S's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $15.45. Genmab A/S's Cyclically Adjusted PS Ratio of today is 17.75.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genmab A/S was 72.33. The lowest was 18.04. And the median was 51.03.


Genmab A/S Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for Genmab A/S's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Cyclically Adjusted Revenue per Share Chart

Genmab A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.13 7.19 8.26 11.84 15.45

Genmab A/S Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.84 12.47 13.33 14.13 15.45

Competitive Comparison of Genmab A/S's Cyclically Adjusted Revenue per Share

For the Biotechnology subindustry, Genmab A/S's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab A/S's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab A/S's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Genmab A/S's Cyclically Adjusted PS Ratio falls into.



Genmab A/S Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Genmab A/S's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=10.364/116.7000*116.7000
=10.364

Current CPI (Dec. 2023) = 116.7000.

Genmab A/S Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.818 99.600 0.958
201406 0.372 99.700 0.435
201409 0.817 99.700 0.956
201412 0.619 99.400 0.727
201503 0.259 100.200 0.302
201506 0.428 100.300 0.498
201509 0.685 100.200 0.798
201512 1.411 99.800 1.650
201603 0.419 100.200 0.488
201606 0.864 100.600 1.002
201609 0.890 100.200 1.037
201612 2.125 100.300 2.472
201703 0.582 101.200 0.671
201706 1.882 101.200 2.170
201709 0.820 101.800 0.940
201712 2.600 101.300 2.995
201803 1.817 101.700 2.085
201806 1.291 102.300 1.473
201809 1.510 102.400 1.721
201812 3.035 102.100 3.469
201903 1.454 102.900 1.649
201906 1.859 102.900 2.108
201909 2.366 102.900 2.683
201912 6.695 102.900 7.593
202003 2.005 103.300 2.265
202006 12.514 103.200 14.151
202009 4.141 103.500 4.669
202012 5.058 103.400 5.709
202103 3.835 104.300 4.291
202106 4.844 105.000 5.384
202109 5.531 105.800 6.101
202112 5.867 106.600 6.423
202203 4.758 109.900 5.052
202206 6.807 113.600 6.993
202209 8.248 116.400 8.269
202212 11.071 115.900 11.147
202303 6.221 117.300 6.189
202306 9.278 116.400 9.302
202309 10.306 117.400 10.245
202312 10.364 116.700 10.364

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


Genmab A/S  (OTCPK:GNMSF) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Genmab A/S's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=274.22/15.45
=17.75

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Genmab A/S was 72.33. The lowest was 18.04. And the median was 51.03.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Genmab A/S Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab A/S (Genmab A/S) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (OTCPK:GNMSF) » Definitions » Cyclically Adjusted Revenue per Share
Address
Kalvebod Brygge 43, Copenhagen, DNK, 1560
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab A/S (Genmab A/S) Headlines

From GuruFocus